Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Dec;30(12):2849-2857.
doi: 10.1111/jce.14229. Epub 2019 Oct 21.

Long-term clinical outcomes from real-world experience of left atrial appendage exclusion with LARIAT device

Valay Parikh  1 , Krzysztof Bartus  2 , Radoslaw Litwinowicz  2 , Mohit K Turagam  3 , Jerzy Sadowski  2 , Boguslaw Kapelak  2 , Magdalena Bartus  4 , Jakub Podolec  2 , Maciej Brzezinski  5 , Dan Musat  6 , Abdi Rasekh  7 , Suneet Mittal  6 , Jie Cheng  8 , Nitish Badhwar  9 , Randall Lee  9   10 , Dhanunjaya Lakkireddy  11
Affiliations
Observational Study

Long-term clinical outcomes from real-world experience of left atrial appendage exclusion with LARIAT device

Valay Parikh et al. J Cardiovasc Electrophysiol. 2019 Dec.

Abstract

Background: Left atrial appendage closure (LAAC) with LARIAT has emerged as one of the alternatives to oral anticoagulation (OAC) in patients with nonvalvular atrial fibrillation (AF). Our aim was to study long-term outcomes in patients undergoing LARIAT procedure.

Methods: We analyzed patients screened for LARIAT device in four centers between December 2009 and June 2012. Out of these, patients who didn't undergo LAAC with the LARIAT device due to unfavorable LAA morphology and other preprocedural contraindications were included in control group. We analyzed thromboembolism, bleeding events, and mortality between LAA and control group.

Results: About 153 patients were screened. Out of these, 108 (70.6%) patients underwent LARIAT placement (LAA arm) and 45 (29.4%) excluded patients were included in control arm. There were no differences in CHADS2 and CHA2 DS2 -VASc score. Mean HAS-BLED score was significantly higher in the LARIAT group (3.5 ± 1.06 vs 3.09 ± 1.22, P = .04). Mean follow-up time (in years) was 6.56 ± 0.84 in LAA and 6.5 ± 1.26 in control arm. During follow-up period, the LARIAT group was associated with significantly less thromboembolic events (1.9% vs 24%, P < .001), bleeding events (9.2% vs 24.4%, P = .03), and mortality (5.6% vs 20%, P = .01) as compared with the control group.

Conclusions: Long-term data from routine clinical practice from our study suggests that LAA exclusion with LARIAT device is an effective treatment in management of nonvalvular AF patients with high risk of stroke, bleeding, and mortality. Further randomized trials, such as aMAZE, will provide more insight in this expanding field.

Keywords: atrial fibrillation; epicardial; left atrial appendage.

PubMed Disclaimer

References

REFERENCES

    1. Bartus K, Bednarek J, Myc J, et al. Feasibility of closed-chest ligation of the left atrial appendage in humans. Heart Rhythm. 2011;8:188-193.
    1. Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation. J Am Coll Cardiol. 2013;62:108-118.
    1. Johnson WD, Ganjoo AK, Stone CD, Srivyas RC, Howard M. The left atrial appendage: our most lethal human attachment! Surgical implications. Eur J Cardio-thoracic Surg. 2000;17:718-722.
    1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370-2375.
    1. Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949-953.

Publication types

MeSH terms

Substances

LinkOut - more resources